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Abstract: Cancer is often characterised by the presence of hypoxia and inflammation. Paramount
to the mechanisms controlling cellular responses under such stress stimuli, are the transcription
factor families of Hypoxia Inducible Factor (HIF) and Nuclear Factor of κ-light-chain-enhancer
of activated B cells (NF-κB). Although, a detailed understating of how these transcription factors
respond to their cognate stimulus is well established, it is now appreciated that HIF and NF-κB
undergo extensive crosstalk, in particular in pathological situations such as cancer. Here, we focus on
the current knowledge on how HIF is activated by inflammation and how NF-κB is modulated by
hypoxia. We summarise the evidence for the possible mechanism behind this activation and how
HIF and NF-κB function impacts cancer, focusing on colorectal, breast and lung cancer. We discuss
possible new points of therapeutic intervention aiming to harness the current understanding of the
HIF-NF-κB crosstalk.
Keywords: NF-κB; hypoxia; inflammation; κB Kinase (IKK); Prolyl Hydroxylases (PHDs); cancer;
Transforming Growth Factor-β-Activated Kinase 1 (TAK1); Factor Inhibiting HIF (FIH)
1. NF-κB Subunits and Signalling Pathways
NF-κB is the collective name of a family of transcription factors initially discovered in 1986
by Ranjan Sen and David Baltimore as a Nuclear Factor binding to the enhancer element of the
immunoglobulin κ light-chain of activated B cells [1]. Over the years, a crucial role in controlling
gene expression in response to inflammation, proliferation, differentiation, among other physiological
processes, has been assigned to the five gene members of this protein family: RelA (p65), RelB, c-Rel,
NF-κB1 (p105) and NF-κB2 (p100) [2,3]. All NF-κB subunits feature high structural similarity, with the
N-terminal harbouring a Rel Homology Domain (RHD). This is essential to mediate DNA binding to
κb sites in enhancers/promoters of target genes, as well as to dimerise with other subunits. In fact,
formation of homo- and heterodimers determines the specificity of the transcriptional response in
accordance with the cellular context [4]. Induction or repression of gene expression is achieved not only
through combination of different NF-κB dimers, but also by physical association with co-activators,
co-repressors, and other transcription factors, such as Signal Transducer and Activator of Transcription
3 (STAT3), p53 [5], or HIFs [6]. A further control of the transcriptional activity also derives from the
C-terminal structure of the NF-κB subunits. In particular, RelA, RelB and c-Rel contain trans-activation
domains (TAs), whereas p105 and p100, precursors of their active forms p50 and p52, contain IκB-like
Ankyrin repeat (ANK) domains, acting as internal inhibitors. Consequently, p50 and p52 can only
function as transcriptional activators in association with other subunits or proteins containing the
trans-activation domain [5,7].
Activation of NF-κB can occur following canonical, non-canonical and atypical pathways,
all triggered by different stimuli, as elegantly reviewed elsewhere [8,9]. Here, we will briefly focus
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only on the canonical and non-canonical mechanisms of activation (Figure 1), which are more likely
to be involved in malignancies. In the canonical NF-κB signalling pathway, the binding of Tumour
Necrosis Factor α (TNF-α), Lipopolysaccharides (LPS), or Interleukin-1 (IL-1) to their specific receptors
on the cellular membrane, induces in the cytoplasm the recruitment of several adaptors and protein
kinases, serving as activation platform, ultimately leading to the phosphorylation and activation of
the Inhibition of κB Kinase (IKK) complex. The IKK complex is formed by two catalytic proteins
(IKK1/IKKα and IKK2/IKKβ) and one regulatory protein (IKKγ/NEMO, NF-κB Essential Modulator).
An activated IKK complex is then able to phosphorylate the IκB inhibitor molecules, which, in quiescent
cells, hold the NF-κB subunits inactive in the cytoplasm. In humans, the most common NF-κB inhibitor
protein is IκBα. Phosphorylation of IκBα on serines 32 and 36 is the key prerequisite for the lysine-48
polyubiquitin chain formation catalysed by SCFβTrCP E3 ubiquitin ligase, and subsequent degradation
mediated by the proteasomal machinery. This event makes the NF-κB dimers free to translocate into
the nucleus, binding the cognate DNA sequence to regulate gene transcription [10]. On the other
hand, the non-canonical NF-κB signalling pathway depends on activation of different membrane
receptors, such as Lymphotoxin β-Receptor (LTβR), B-cell Activation Factor Receptor (BAFFR), TNF
Receptor 2 (TNFR2) and several others. The consequent signal transduction involves the activation
of the NF-κB Inducing Kinase (NIK) that, in turns, phosphorylates and activates IKKα homodimers.
This event is followed by specific phosphorylation of serines 866 and 870 at the C-terminal region of
p100, resembling the phosphorylation site of IκBα. Upon binding of the SCFβTrCP ubiquitin ligase,
the inhibitor ankyrin repeat domain of p100 is subject to proteasomal processing. Thus, the cleaved
active form p52 originates and associates with RelB, serving as transcriptional activator heterodimer
after translocation into the nucleus [7].
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Figure 1. Activation pathways for canonical and non-canonical NF-κB signalling. Canonical NF-κB
pathway is exemplified by TNF-α binding to its reception, while non-canonical NF-κB pathway is
illustrated by binding of LT-β to its receptor.
In general, the fine tuning of the NF-κB response is controlled by different post-translational
modification events, such as phosphorylation, as well as by an intricate series of protein-protein
interactions and feedback loops. The fact that IκBα itself is one of the NF-κB target genes represents
an example of negative feedback. The newly synthesized IκBα is able to relocate NF-κB subunits
from the nucleus to the cytoplasm. Also, considering the important role of K63-linked or linear
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polyubiquitination as a platform for the activation of the NF-κB pathway, de-ubiquitinase (DUB)
enzymes, such as Cyld or A20, can serve as negative feedback inhibitors of the pathways [5]. When
the regulatory mechanisms described above become aberrant, NF-κB can become constitutively active
or deregulated. For instance, NF-κB is chronically activated in several inflammatory diseases, such
as arthritis, inflammatory bowel disease, asthma and many other pathological conditions, including
cancers [11,12]. Here, we will discuss the role of NF-κB in cancer, focusing on how this transcription
factor can be induced by hypoxia, and modulated by HIF, in a variety of tumour contexts.
2. NF-κB in Inflammation and Cancer
Activation of the NF-κB pathway is widely recognised as characteristic of inflammation.
Inflammation is a defensive process used by the innate and adaptive immune systems to respond
to bacterial and viral infections, facilitating wound healing or maintenance of tissue homeostasis.
In the last fifteen years, chronically prolonged inflammatory response has been identified as a
hallmark of cancer [13]. However, the role of NF-κB in malignancies remains quite controversial,
acting as tumour promotor or tumour suppressor depending on the cellular context [14]. In cancers
featuring a chronic inflammatory microenvironment, NF-κB is conspicuously activated. Thus, cancer
development is further promoted, and tumour progression is reinforced. In fact, in these tissues,
pro-inflammatory cytokines (i.e., TNF-α, IL-1, interleukin-6 (IL-6)), Reactive Oxygen and Nitrogen
Species (RONS), prostaglandins, and microRNAs accumulate, contributing to create a pro-tumorigenic
microenvironment. In particular, a constitutive activated NF-κB participates in carcinogenesis
stimulating cell proliferation, inhibiting programmed cell death, regulating angiogenesis, promoting
tumour metastasis and remodelling tumour metabolism [14]. NF-κB influences cell proliferation
by controlling autocrine and paracrine production of cytokines, such as Interleukin-2 (IL-2) and
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) [15]. Additionally, NF-κB controls
gene expression of G1 cyclins, such as cyclin D1 [16], which is a crucial protein in the exit from the G1
phase of the cell cycle, frequently altered in numerous human cancers [17].
NF-κB plays a dual role in controlling apoptosis. Several reports have supported a pro-apoptotic
activity of NF-κB [18,19]. However, NF-κB ability to prevent apoptosis seems to be more often
studied, leading to the activation of target genes such as cellular Inhibitors of Apoptosis (cIAP1/2,
XIAP), cellular FLICE (Caspase8/FADD-like IL-1β-Converting Enzyme)-Inhibitory Protein (c-FLIP),
and members of the Bcl2 family, such as Bcl-xL [20]. Such anti-apoptotic roles of NF-κB might be
determinant during cancer progression, when cells that have undergone DNA damage or chromosomal
rearrangements can therefore escape from apoptosis, overcoming also other checkpoint controls
normally operated by p53, a tumour suppressor mutual antagonist of NF-κB [21].
Expansion of vascular network, also termed angiogenesis, is one of the main hallmarks of tumour
growth [13]. A number of NF-κB target genes are known to be involved in this process. Among
them there are the chemokine Interleukin-8 (IL-8) [22], and the Vascular Endothelial Growth Factor
(VEGF) [23]. Anti VEGF strategies have been successful in the clinic for treatment of patients with
several cancers, including colorectal cancer (CRC) (reviewed in [24]), in the form of Bevacizumab,
a monoclonal antibody against VEGFA, and Aflibercept, a recombinant fusion protein blocking VEGFA
and VEGFB signalling. Interestingly, these genes can be also targets of HIF-1α [25,26], highlighting the
existence of an intricate crosstalk between inflammation and hypoxia in cancer cells (see Section 4).
NF-κB also directly regulates expression of genes encoding for matrix metalloproteinases, such
as MMP-9 [27]. Extracellular matrix remodelling not only facilitates the spread of endothelial cells
(angiogenesis), but also of cancer cells (metastasis) in the surrounding areas. Notably, a role of NF-κB in
tumour metastasis formation has been reported in human head and neck squamous cell carcinoma [28],
and breast cancer [29].
As part of the immune response, NF-κB can exert also tumour suppressing functions. In particular,
this occurs in some acute inflamed environments, when Cytotoxic T cells (CTL) are highly activated
against malignant cells [30], or in chemically induced liver and skin cancers [31,32]. However, this
Biomedicines 2017, 5, 21 4 of 23
response might be not able to eradicate all aberrant cells, which then escape the immune system.
Chronic inflammation in the microenvironment, and, consequently, the increased cytokine release
elevates the NF-κB activity, resulting in tumour promotion. However, the NF-κB activity can be
enhanced also by mutation of NF-κB pathway components and/or oncogenes [33]. Mutation of NF-κB
occurs in particular in lymphoid malignancies, such as human B cell- [34,35] or T cell-lymphomas [36].
Although less frequently, mutations of the NF-κB signalling pathway occur also in solid tumours.
For instance, mutations in NF-κB1 have been detected in breast cancer [37]. In addition, most recently,
high expression of IKKα has been associated with poor outcome in patients with Estrogen Receptor
(ER)-positive invasive ductal breast cancer, although its expression appeared to be independent of
NIK and RelB [38]. Overall, the NF-κB pathway has been found to be fundamental in development,
maintenance, or invasiveness of multiple solid cancer types, including colon and lung cancers [39–41],
hepatocellular carcinoma [42], and melanoma [43]. While not all cancers form in inflamed tissues,
inflammation arises as a consequence of metabolic dysregulation associated with tumour development,
facilitating the progression of the tumour itself. During tumour propagation, the high demand of
oxygen and nutrients creates a pathologic hypoxic microenvironment in the tumour core, inducing the
production of angiogenic growth factors and cytokines, to form new blood vessels and recruit more
innate immune cells [44]. Indeed, hypoxia strongly impacts on tumour progression and metastasis, by
activating specific transcriptional programmes, such as HIF and NF-κB [45].
3. Hypoxia and Hypoxia Inducible Factor (HIF) Pathway
Hypoxia, or diminished oxygen availability, is a common feature of the tumour microenvironment,
where the oxygen level is often below 1%. This condition triggers a series of gene expression
changes, affecting angiogenesis and metabolism, to enable tumour survival and progression [45].
Hypoxia in tumours occurs in different areas, from anoxic regions further away from the blood
vessels to hypoxic areas, generated by highly metabolic cancer and immune cells [45,46], creating a
non-uniform tumour microenvironment. The main molecular drivers of this response belong to a
family of basic Helix-Loop-Helix-Per-ARNT-Sim (bHLH-PAS)-containing transcription factors, known
as HIFs [47]. HIF is a heterodimeric complex formed by an oxygen-dependent α subunit and an
oxygen-insensitive β subunit. In fact, the constitutively expressed HIF-1β (also called ARNT, Aryl
Hydrocarbon Receptor Nuclear Translocator) is the obligatory binding partner for any HIF-α. So far,
three α-forms (HIF-1α, -2α and -3α) have been identified in humans. HIF-1α, the most well-studied
isoform, is ubiquitously expressed, while HIF-2α expression is restricted to endothelial cells, heart,
lung, placenta and kidney [48]. Only recently the expression profile of the several HIF-3α spliced
variants has been elucidated, with HIF-3α predominantly expressed in kidney and lung epithelial
cells [49]. Interestingly, although HIF-1α and HIF-2α are structurally closely related, and despite some
redundancy in their functions with the sharing of several common target genes, they also have distinct
target gene cohorts [50]. Moreover, their roles can vary depending on tumour and cell types [51]. HIF-3α
function remained unclear for long time, being mainly considered a dominant negative regulator of
the other HIF-α isoforms, by competing for HIF-1β binding [50]. Only recently, a novel transactivation
activity induced by hypoxia has been attributed to HIF-3α in zebrafish embryos, opening new scenarios
in the regulation of transcriptional response following exposure to low oxygen [52].
The cellular response to hypoxia engages HIF primarily at the post-transcriptional level, where
the HIF-α proteins stability is regulated by non-heme, Fe2+ and 2-oxoglutarate (2OG)-dependent
dioxygenase enzymes called Prolyl Hydroxylases (PHDs). Under normal oxygen conditions, PHDs
(PHD1, PHD2 and PHD3) hydroxylate specific proline residues within the Oxygen Dependent Domain
(ODD) of the HIF-α subunit. Thus, the hydroxylated HIF-α is recognised by the von Hippel-Lindau
(vHL) tumour suppressor protein, component of an E3-ubiquitin-ligase complex. This leads to HIF-α
Lys48-linked poly-ubiquitination and subsequent proteasomal degradation. In addition, further control
of transcriptional activity of HIFs escaping degradation is mediated by FIH (Factor Inhibiting HIF).
This 2OG-dependent dioxygenase enzyme prevents HIF association with the co-activators p300/CREB
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Binding Protein (CBP), by hydroxylation of a key asparagine in the transactivation domain of HIF-α.
In hypoxia, PHDs and FIH are inactive, due to the absence of oxygen, essential cofactor for these
enzymes [53]. This enables the hypoxic transcriptional programme to occur. The stabilised HIF-α
subunit translocates into the nucleus, dimerizes with HIF-1β, and, upon binding to the consensus
hypoxia response element (HRE), transactivates downstream target genes, involved in a large variety
of processes, including glycolysis, angiogenesis, proliferation, migration, and apoptosis [54] (Figure 2).
As crucial mediators of several biological and cellular processes, both HIF-1α and HIF-2α expression
are elevated in numerous solid tumours, such as colon, breast and lung cancers [48]. For instance, high
levels of HIF-1α correlate with poor clinical outcomes in human breast cancer, with HIF-1α being the
master regulator of Epithelial-Mesenchymal Transition (EMT), invasion, extravasation, and metastasis
in this type of tumor [55].
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Figure 2. Activation of the Hypoxia Inducible Factor (HIF) pathway in response to hypoxia. HIF-α
levels are controlled in normoxia by PHD-mediated hydroxylation (OH) and recognition by the
E3-ligase complex containing the tumour suppressor pVHL. In hypoxia, Prolyl Hydroxylases (PHDs)
and FIH are inhibited and HIF-α escapes VHL-dependent degradation. T-bars represent repression.
A relevant role as regulators of the hypoxic response has been recently attributed to the Jumonji C
(JmjC) domain containing proteins [56], many of which are 2-OG dioxygenases functioning as protein
demethylases. These enzymes, of which there are over 30 discovered in humans, mainly control histone
methylation, and they are often deregulated in many cancers (reviewed in [57]). Structural work
from the Schofield and Allshire laboratories has revealed that the domain responsible for demethylase
activity of these nzymes (JmjC domain) has a fold that is remarkably similar t the catalytic core of
FIH [58,59]. In addition, inv stigation of the oxygen depe dency of two of hese enzyme revealed a
graded drop in activity over physiologically relevant ranges of oxygen [60,61]. These studies indicate
the potential of JmjC enzymes to link chromatin structure to oxygen sensing and participate in the
hypoxia mediated transcriptional response. Indeed, an increasing number of reports found elevated
histone methylation marks in response to prolonged hypoxia [62–65], with the impaired JmjC enzyme
activity being responsible for these changes [63,65]. Interestingly, many of these enzymes are hypoxia
inducible (reviewed in [57]), with some, including Lysine (K)-specific demethylase 4B (KDM4B),
KDM4C, KDM5B, KDM3A, KDM2A and KDM2B, being HIF targets [66–71]. This may point to negative
feedback mech nism to help regulate histone methylation in a JmjC histone demethylase compromised
environment, and possibly help the cell reset its oxygen sensing and response mechanisms after
prolonged hypoxia and/or restoration of normoxia, as is seen with PHD regulation of HIF.
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4. Crosstalk between Hypoxia and Inflammation in Cancer
Recently, an increasing number of studies supported a role of HIF beyond the hypoxia
response [72]. HIF-1α activation has been detected following different bacterial infections under
normal oxygen levels [73], whereas HIF-2α and HIF-1β have been found to regulate neutrophilic
inflammation and myeloid cells function in wound healing, respectively [74,75]. In inflammation,
mechanisms leading to HIF induction can be oxygen-independent, and mediated by other transcription
factors, such as STAT3 [76] and NF-κB [77,78]. In recent years, an intimate crosstalk between HIF
and NF-κB has been appreciated at different levels, as reviewed in [6]. Interestingly, this crosstalk
is bi-directional. In fact, not only does NF-κB induce HIF (Figure 3A), but HIF regulates NF-κB
(Figure 3B). Particularly, under inflammatory conditions, NF-κB transcriptional activity is restricted by
HIF-1α in vivo and in vitro [25]. To date, the knowledge concerning HIF-2α and HIF-1β contribution
to the NF-κB activity is still poor, despite the fact that these HIF subunits have been associated with
NF-κB [79,80].
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pathway; (B) Reported points of interaction and control of the HIF pathway over the NF-κB signalling
cascade. Red T-bars indicate inhibition points, whereas arrows with dashed lines indicate regulation
events t at av not been prov d in an in vivo system yet. Question marks are used to highlight the
unanswered questions into the HIF regulation of the NF-κB pathway.
HIF can directly contribute to the inflammatory response, inducing several pro-inflammatory
chemokines and cytokines [12]. Importantly, numerous genes transcriptionally activated by HIF are
also NF-κB target genes involved in tumorigenesis, such as IL-6, MMP9, cyclooxygenase 2 (COX2),
as well as pro-survival genes, such as Bcl-2, among others [81]. Indeed, the cooperative relationship
between HIF and NF-κB in the tumour-associated inflammatio is evident. Mor pro-inflammatory
mediators are produced in the hypoxic areas of the t mours, resulting in the recruitment of more
immune cells at neoplastic sites. This determines a chronic inflammation in the tu our, with
consequent high activation of NF-κB [12]. As previously stated, inflammation is a key player in
tumour development and progression, therefore it is not surprising that chronic inflammatory diseases
may predispose to cancer. One example is the Inflammatory Bowel Disease (IBD), a chronic intestinal
disorder including Crohn’s disease and ulcerative colitis [11]. Patients affected by this condition
have a greater risk to develop colon cancer, particularly Colitis-Associated Colon cancer (CAC) [82].
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In colon tumorigenesis, where hypoxic inflammation is significant, both HIF-1α and HIF-2α are
expressed [48]. Notably, a recent study highlighted the importance of intestinal epithelial HIF-2α in
the recruitment of neutrophils to colon tumour sites, supporting its prominent role in the inflammatory
microenvironment [83]. Another example of hypoxia and inflammation crosstalk in cancer is observed
in Hepatocellular Carcinoma (HCC), where TNF-α is one of the cytokines constantly activated by
NF-κB, through the Tumour Associated Macrophages (TAMs). The expression of HIF-1α and HIF-2α
in these immune cells seems to be particularly important in the HCC progression [12,84]. However,
to better understand the precise mechanisms, by which hypoxia and immune cells contribute to the
intra-tumoural inflamed microenvironment, further studies are needed.
5. Hypoxia-Induced NF-κB
As mentioned earlier, NF-κB is one of several transcription factors induced by hypoxia. Although
mechanisms by which NF-κB is activated under low oxygen are still under investigation.
5.1. Role of the Oxygen Sensors in the Hypoxia Induction of NF-κB
5.1.1. Hydroxylases
2OG-dependent dioxygenases, such as PHDs and FIH, function as oxygen sensors stabilizing
HIF in hypoxia, therefore these and other dioxygenases may confer oxygen sensitivity to additional
pathways regulated by oxygen availability, including NF-κB. Indeed, the discovery of new and
potential FIH and PHD targets supports this. Proteomics approaches have revealed NF-κB pathway
components, including p105 and IκBα [85] as well as an upstream regulator of the NF-κB pathway,
OTU dDe-ubiquitinase, Ubiquitin Aldehyde Binding 1 (OTUB1), as being hydroxylated by FIH [86,87].
Although these novel FIH targets provide promising links to NF-κB and oxygen sensing, with the
exception of OTUB1 [87], mutational analysis has been unsuccessful in identifying any functional
significance for these modifications [85,88]. Although OTUB1 hydroxylation by FIH regulates metabolic
processes in the cell [87], a role of OTUB1 in activating the NF-κB pathway under hypoxic conditions
has yet to be established. Interestingly, other players in the IL-1β pathway, the ubiquitin ligase enzymes
Uve1a and Ubc13, are also targets for hydroxylation [86]. These enzymes have also been shown to be
required for hypoxia induced NF-κB activity [89,90]. Thus, although speculative, oxygen regulated
hydroxylation of these ubiquitin ligases could play a part in the NF-κB induction by hypoxia.
As with FIH, whilst there is evidence of PHD regulation of NF-κB induction following oxygen
deprivation, a direct oxygen sensing mechanism mediated by PHD prolyl hydroxylase activity has not
been discovered yet. PHDs have been found to antagonise NF-κB activity in various cell types [91–95].
Hypoxia induction of NF-κB via IKK activation has been shown to be regulated by PHD1 and, to a lesser
extent, by PHD2 levels [91]. The authors of this study suggested a PHD prolyl hydroxylase dependent
mechanism, providing evidence that IKKβ is a potential PHD target through the identification of
conserved PHD prolyl hydroxylation motif, which is required for the hypoxia induction of IKKβ levels.
Further supporting this finding, Zheng and colleagues identified IKKβ among the PHD1 substrates
in a hydroxylation screening assay [96]. However, further studies are required to demonstrate IKK
hydroxylation in cells. Conversely, another group has found that PHD3 inhibits NF-κB by a prolyl
hydroxylase-independent inhibition of IKKγ ubiquitination [94]. In addition, a cooperative role of
PHD2 with respect to NF-κB activity, functioning as coactivator of p65, has been shown [97]. Taken
together, these studies exemplify the cell type and context specificity of hypoxia induced NF-κB
regulation by PHDs.
5.1.2. JmjCs
The aforementioned JmjC enzymes also link NF-κB activities’ in hypoxia to oxygen sensing.
Despite methylated histone lysine residues being the prominent target for the demethylating activity
of these enzymes, non-histone targets are emerging. KDM2A has been shown to demethylate p65,
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inhibiting expression of some of its target genes [98,99]. Various methylation sites have been identified
on p65 [98,100–102]. Both K218 and K221 methylation sites are reversibly regulated by Nuclear
Receptor Binding SET Domain Protein 1 (NSD1) and KDM2A, with NSD1 methylating them in
response to IL-1β induction, aiding the activation of a subset of NF-κB target genes. Interestingly,
KDM2A is NF-κB inducible [98] as well as hypoxia inducible in HIF-1 dependent manner, as recently
shown by our group [71]. This represents another feedback loop of NF-κB regulating its own activity,
and may confer another level of crosstalk between low oxygen availability and NF-κB function.
KDM2B, the other member of KDM2 family member, is also hypoxia and NF-κB inducible [71,103];
however, it is currently unknown if this enzyme influences NF-κB activity. Another NF-κB induced
JmjC enzyme, KDM6B, promotes activation of a subset of genes in LPS activated macrophages in a
histone demethylase independent manner [104]. Furthermore, JMJD8 has been shown to positively
regulate TNF induced NF-κB signalling, although the mechanism by which this occurs has not
been elucidated [105]. These reports further highlight some known and potential crosstalk points
between hypoxia and NF-κB. Emergence of new JmjC targets and functions may lead to new NF-κB
regulatory links.
5.2. TAK and IKK in Hypoxia Induced NF-κB
An IKK independent mechanism of action was reported when hypoxic activation of NF-κB
was initially discovered [106]. Since this seminal work, it has been shown that IKK dependent
mechanisms of NF-κB activation in response to hypoxia do occur [72,107,108]. Our laboratory has
shown that NF-κB responds rapidly to hypoxia in an IKK dependent manner in cancer and primary
cell lines. Specifically, IKK mediates hypoxia induced phosphorylation of IκBα at serine 32 and 36 and
also influences DNA binding of NF-κB [90,107]. This mechanism is dependent on the E2 ubiquitin
conjugating enzyme Ubc13 [107], and XIAP may be one the E3 ligases interacting with Ubc13 in
hypoxia-induced NF-κB activation [90]. We went on to show that hypoxia-induced IKK-mediated
NF-κB activation is conserved in Drosophila [109]. This work also found that the MAPK family
member TAK1 (Transforming Growth Factor-β-Activated Kinase 1) was part of the mechanism of
hypoxia-induced NF-κB. Further investigation into other potential regulatory mechanisms of hypoxia
induced NF-κB activation, particularly cell/tissue specific regulators, are required.
5.3. Role of IκBα in the Hypoxia Induction of NF-κB
As mentioned above, inactivation of the NF-κB inhibitor IκBα by TAK-IKK mediated serine
phosphorylation can induce hypoxia-induced activation of NF-κB. Mutational analysis shows that
this mechanism appears to be independent of IκBα tyrosine phosphorylation [107], for which a role
was initially suggested [106]. Hypoxia induction of NF-κB is atypical since IκBα is not degraded
as ubiquitination is inhibited and replaced with sumoylation in low oxygen environments [107].
There are currently various models of IκBα sumoylation influencing NF-κB activity in different
cellular contexts [110,111]. Sumo 2/3 conjugation of IκBα may be important in hypoxia-induced
NF-κB activation, whilst Sumo 1 conjugation has been shown to inhibit NF-κB. Inactivation of Sumo
proteases in hypoxia is a potential mechanism whereby 2/3 conjugation of IκBα is present in hypoxia.
Interestingly, polycomb complex regulated transcription has been shown to be influenced by nuclear
IκBα phosphorylation and sumoylation [112]. Transcriptional control regulated by IκBα sumoylation
in hypoxia represents a new area of research in the field of inflammation following hypoxia.
6. Hypoxia-Dependent NF-κB Activation in Cancer
6.1. Colorectal Cancer
Colorectal cancer (CRC) affects over 500,000 people each year, and is the fourth most common
cause of cancer related mortalities [113]. The intestinal lumen of a CRC patient is characterised by
both inflammatory and hypoxic regions (reviewed in [11]). NF-κB is activated in CRC in response
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to inflammation, promoting tumorigenesis and cancer progression [114]. Multiple pathways are
implicated in NF-κB oncogenic role in CRC, including Reactive Oxygen Species (ROS) production,
activation of pro-inflammatory cytokines, cell survival, EMT, cell proliferation, migration and
angiogenesis (reviewed in [11]). Blocking NF-κB signalling has been shown to impair tumour growth
in mouse models of CRC and CAC [40,115]. Moreover, anti-inflammatory drugs are used in the
clinic to target chronic inflammation in CRC. These are mainly Non-Steroid Anti-Inflammatory
Drugs (NSAIDs), which inhibit cyclooxygenase enzymes including COX2, upregulated by NF-κB.
Like most solid tumours, hypoxia promotes tumorigenesis and progression in CRC. As mentioned
earlier, effects of HIF-1α and HIF-2α on cancer is context specific. In CRC they have antagonising
roles, with HIF-1α acting oncogenic and HIF-2α acting tumour suppressive [116]. High HIF-1α
levels are associated with poor CRC prognosis. The role of HIF-1α in potentiating CRC through
metastatic and angiogenic pathways has been characterised in several reports [117–121]. Conversely,
transcript analysis on 120 CRC patient samples found that low HIF-2α mRNA is a prognostic factor,
correlating with increased risk of mortality [122]. Another study performed immunohistochemically
analysis on 63 primary tumour samples, finding an anti-correlation between HIF-2α levels and tumour
stage [116]. The aforementioned study also used mouse xenografts showing siRNA depletion of
HIF-1α reduces tumour growth whereas the opposite is seen in HIF-2α depletion. Additionally,
HIF-1α knock-down in colon cancer cells increases cell proliferation, and, although HIF-2α has
no effect on cell proliferation, colony formation was increased in a soft agar assay for anchorage
independent growth [116]. Pharmacological inhibition of HIF has also been shown to result in tumour
regression in a murine model of CAC, with a reduction in TAM infiltration [123]. As the above data
demonstrates, NF-κB and HIF-1α are key components in driving CRC development and growth.
Apoptosis, cell proliferation, angiogenesis and EMT are some overlapping pathways in the crosstalk
between inflammatory and hypoxic signalling in CRC.
Around 70% of CRCs follow a distinct mutational sequence, starting with mutations in the
tumour suppressor Adenomatous Polyposis Coli (APC) followed by V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS), p53 and DCC (Deleted in Colorectal Cancer) mutations. The oncogene
c-myc is also commonly overexpressed. The initial APC mutations trigger adenoma formation,
which can develop into CRC [124]. APC supresses Wnt/β catenin signalling, which limits cell
proliferation through the T-Cell Factor/Lymphoid Enhancer Factor (TCF/LEF) pathway [125,126].
APC, HIF-1α and β catenin are in cross regulatory network. APC is a HIF-1α target gene repressed
in hypoxia, activating cell proliferation via increased Wnt/β catening signalling [127]. Moreover,
APC can indirectly repress HIF-1α in a β catenin and NF-κB dependent fashion [127]. Furthermore,
β catenin regulates NF-κB in a dose dependent manner. β catenin can activate NF-κB signalling
through a positive feedback loop, however at higher levels β catenin can repress NF-κB (reviewed
in [128]). β catenin levels have also been recently shown to be regulated by KDM2A and KDM2B [129].
Demethylation of non-phosphorylated β catenin by KDM2A and KDM2B induces nuclear degradation
of β catenin and loss of Wnt/β catenin signalling. Given the importance of APC in CRC, gaining a
better understanding of this complex crosstalk between HIF, NF-κB and APC pathways may give
better insight into understanding molecular mechanisms behind CRC.
Another connection point between HIF and NF-κB pathways is c-myc. c-myc promotes cell
proliferation and is typically overexpressed in transformed cells. HIF-1α inhibits c-myc activity and
functioning via multiple mechanisms, including direct interaction, induction of Mx1 and activation
of p21 [130–133]. Paradoxically, in an oncogenic environment where c-myc is overexpressed, HIF
does not impair c-myc driven cell proliferation; instead, c-myc and HIF-1α collaborate to potentiate
activation of metabolic proteins, such as Pyruvate Dehydrogenase Kinase 1 (PDK1) and Hexokinase
2 (HK2), driving the Warburg effect, and VEGF, driving angiogenesis (reviewed in [134]). c-myc is
also transcriptionally upregulated by NF-κB, along with p21, conferring cell proliferative effects of
NF-κB [16,135]. Furthermore, c-myc transcriptional activity on a subset of its targets driving cell
growth is augmented by HIF-2α [136].
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EMT is crucial for cancer progression, enabling invasion, and thus initiation of metastasis.
The EMT driving transcription factors Snail and Twist are components co-regulated by NF-κB and
HIF with potential clinical significance in CRC. Twist enhances EMT, Snail promotes lymph node
metastasis in CRC [137]. Both are upregulated by hypoxia in a HIF dependent manner [138–140].
Also, HIF-1α upregulation of Twist in response to hypoxia or HIF-1α overexpression induce EMT and
metastatic phenotypes [139]. TNF-α induction of NF-κB signalling, stabilising Snail and β catenin, also
promotes EMT [141]. Moreover, high levels of Twist and NF-κB are associated with tumour metastasis
to the lymph nodes [142]. Hypoxic and inflammatory stimuli in the tumour microenvironment can
coordinate the infiltration TAMs to the tumour. TAMs can be tumour inhibitory or tumour promoting.
Furthermore, low oxygen and chronic inflammation can subvert normal macrophage function from
cancer killing (M1 classically activated) to cancer survival and growth (M2 alternatively activated).
TAMs polarized towards the M2 state potentiate immunosuppressive, metastatic and angiogenic
signals. NF-κB is activated by infiltrating macrophages and TAMs through release of growth factors
and cytokines (reviewed in [143]), and is central to subverting TAM function. As mentioned earlier,
pharmacological inhibition of HIF has also been shown to result in tumour regression in a murine
model of CAC, with a reduction in TAMs infiltration [123]. The group identified a potential mechanism
for the reduced TAM infiltration in this model through loss of Macrophage Colony Stimulating Factor
Receptor (M-CSFR), a HIF target gene that is key signal for recruitment of macrophages to a tumour
environment. The role played by TAMs in CRC progression is somewhat controversial. There is
accumulating evidence for both tumour surviving and tumour killing phenotypes. It seems that which
activity is dominant is dependent on where TAMs are located in CRC and the extent to which they
have M1 or M2 like activities. Nonetheless the role of hypoxia and inflammation in tumour promoting
functions of TAMs are well established. The development of therapies to polarize the TAM pool in
CRC towards an M1 phenotype does seem attractive.
JmjC enzymes are emerging as new therapeutic targets and potential biomarkers in several
cancers, including colon cancer. Given that KDM2A directly repressed NF-κB transcriptional activity
via p65 demethylation [98], it would be anticipated that KDM2A activity may influence NF-κB driven
cancer phenotypes. In the same study identifying KDM2A as demethylating p65, the authors showed
that KDM2A impairs NF-κB dependent colon cancer cell growth [98]. Transcript analysis of colorectal
liver metastases has identified the HIF-1α target KDM3A, as a biomarker for hypoxic tumour cells and
potential prognostic marker and therapeutic target for CRC [69,144]. Another JmjC containing protein,
KDM6B, is transcriptionally induced by vitamin D, and KDM6B mediates a subset of effects of vitamin
D on colon cancer [145]. Specifically, KDM6B deletion induces the expression of pro EMT factors
including Snail, and mesenchymal markers. KDM6B depletion was also shown to block vitamin D
regulation of β catenin export. Moreover, KDM6B expression anti-correlates with Snail expression and
correlates with vitamin D receptor expression [142].
PHD3 may function as a tumour suppressor in CRC through inhibition of IKKβ-mediated NF-κB
signalling [146]. PHD3 has reduced expression in CRC compared to normal tissue and expression of
PHD3 anti correlates with tumour severity [146]. Furthermore, PHD3 inhibits TNF-α induced NF-κB
activity in colon cancer cell lines by blocking phosphorylation of IKKβ. This mechanism was shown
to be independent of PHD3 hydroxylase activity, and via PHD3 blocking the interaction between
IKKβ and Heat Shock Protein 90 (HSP90), an interaction required for IKKβ phosphorylation [146].
Control of p53 regulated apoptosis is another point of potential PHD-NF-κB crosstalk with clinical
significance in CRC. PHD1 has been shown to aid the p53 mediated CRC resistance to genotoxic
agents [147]. p53 phosphorylation, mediated by p38α kinase in response to chemotherapy, can
inhibit chemotherapy-induced apoptosis through p53-induced DNA repair. Researchers found that
silencing of PHD1, but not PHD2 or PHD3, prevented p53 activation in response to genotoxic
treatment [147]. Moreover, PHD1 sensitized colorectal cancer to 5-FU treatment in mice [147].
Mechanistically, PHD1 was reported to enhance the p53-p38α kinase interaction, and subsequent
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p53 phosphorylation, in response to genotoxic damage in CRC in a hydroxylation-dependent and
HIF-independent manner [147].
6.2. Breast and Lung Cancer
Breast and lung cancer are other examples of solid tumours where inflammation and hypoxia are
fundamental drivers of disease progression. HIF and NF-κB signalling pathways have been established
as playing oncogenic roles suitable for targeting. The usual players in inflammatory and hypoxic
signalling crosstalk in cancer, such as TAMs, VEGF, and p53 have mechanistic importance in these
diseases, as does the less well characterised crosstalk component, JmjC enzymes. In cell culture, IKK
inhibition blocks Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) activation of NF-κB and induces apoptosis
in ER negative ERBB2 positive breast cancer cells [148]. In vivo, inhibition of NF-κB impairs tumour
progression in a murine model of breast cancer [148]. Furthermore, NF-κB dependent induction of
EMT has been shown in breast cancer models [29,149]. There is also evidence of Epidermal Growth
Factor (EGF) signalling enhancing NF-κB activity in breast cancer [150]. In this context, mechanism of
activation of NF-κB by EGF may be similar to that described in lung cancer, where an IKK independent
mechanism mediated by tyrosine kinase phosphorylation of IκBα is in place [151]. NF-κB activation
is particularly prevalent in lung adenocarcinomas with constitutively active EGF-Receptor (EGFR)
mutations. It can drive resistance of tumours to receptor tyrosine kinase inhibition, demonstrating the
potential of targeting NF-κB to improve patient outcome in EGFR mutant lung cancer sufferers treated
with receptor tyrosine kinase inhibitors [152]. An oncogenic role of HIF-1α in breast cancer has been
well characterised (reviewed in [153]). Drugs inhibiting HIF, namely acriflavine, digoxin and topotecan
impair tumour growth and metastasis in animal models of breast cancer [154–156]. Non-Small-Cell
Lung Carcinoma (NSCLC) is highly metastatic and the most common form of lung cancer. HIF-1α
and -2α subunits and frequently overexpressed in NSCLC, along with VEGF, which is targeted for
treatment of NSCLC. HIF signalling has been shown to induce TAM mediated angiogenesis in human
breast carcinoma models, and HIF-2α/TAM signalling may be a useful antiangiogenic breast cancer
therapy [157,158]. Along with VEGF, Arginase 1 (Arg1) is transcriptionally induced by TAMs in
response to HIF signalling. Arg1 also contributes to the tumour survival and growth activities of
TAMs, and is elevated in mouse cancer model TAMs and in myeloid cells of breast cancer patients [159].
Several hypoxia-inducible HIF target JmjC enzymes are deregulated in breast and lung cancer. The
KDM4 family members of JmjC enzymes, targeting di- and trimethylated H3K36 and H3K9, namely
KDM4A, KDM4B and KDM4C are upregulated in breast cancer [160–162]. KDM4B has been found to
mediate oestrogen stimulated cell proliferation of mammary cancer [163]. This study also found that
KDM4B is transcriptionally induced by ERα in MCF7 cells and upregulates ERα target genes. Control
of ERα target gene expression in mediated by fine tuning of H3K4 and H3K9 methylation at ER target
promoters through a complex of KDM4B and the H3K4 methyltransferase MLL2 [163]. The H3K4
demethylase KDM5B has transcriptional repressor functions and is also a coactivator of the androgen
receptor. KDM5B is overexpressed in both lung and breast cancer [164,165]. Furthermore, oncogenic
functions of KDM5B have been demonstrated in vitro and in vivo. In MCF7 cells and in a mouse
breast cancer model, depletion of KDM5B inhibits cell growth [166]. This correlates with suppression
of the tumour suppressor gene BRCA1 [166]. More recently, high KDM5B expression was found to
correlate with poor prognosis in breast cancer patients and enhanced breast cancer invasiveness in
triple negative breast cancers [167]. Authors in this study also identified a mechanism for increased
breast cancer invasion involving a KDM5B-metastasis-associated lung adenocarcinoma transcription
(MALAT1)-hsa miR448 signalling axis [167]. A role of KDM5B is also present in lung cancer whereby
KDM5B suppresses p53 expression [168]. This could have a functionally relevant link to NF-κB in lung
cancer. Concomitant loss of p53 function and constitutively active KRAS control enhanced NF-κB
activity in lung cancer cell lines and a mouse model of lung cancer [169]. Given the evidence for
KMD5B driving cancer progression in the breast and lung cancers, it is perhaps no surprising that
small molecule inhibitors against it are in development for use as potential cancer drugs. The small
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molecule inhibitor of KDM5B, EPT-103182 [170], has yielded promising results with anti-proliferative
effects in various cancer cell lines and anti-tumour effects in mouse cancer models [171]. KDM2A
along with KDM5B, have the highest frequency of gene amplifications and over expressions in breast
cancer with respect to JmjC enzymes [172]. Interestingly the small isoform of KDM2A, which lacks the
JmjC domain, is more highly expressed than the full isoform in a subset of breast cancer, suggesting an
oncogenic role KDM2A independent of direct demethylase activity [172]. A potential mechanism for
NSCLC progression in a subset of patients overexpressing KDM2A has been reported, with KDM2A
stimulating cell proliferation through ERK1/2 signalling [173].
Studies on the importance of PHDs in breast and lung cancer are fairly limited. However, there
is evidence of an important role of PHD1 in breast cancer through regulation of cell proliferation.
Knockdown of PHD1 in breast cancer cell lines reduces cell proliferation and this correlates with
loss of cyclin D1 [174]. Cyclin D1 stimulates cell cycle progression through its interaction with
Cyclin Dependent Kinases (CDKs). Forkhead Box O3a (FOXO3a) was then identified as a new
target for PHD1 [96]. Hydroxylation of FOXO3a by PHD1 has been shown to regulate cyclin D1
transcription, representing a potential mechanism by which PHD1 loss in breast cancer can impair cell
growth. Conversely, treatment of breast cancer cell lines and a mouse xenograft model with docetaxel,
a potential breast cancer drug, causes cell death in hypoxic conditions through c-Jun N-terminal
Kinase 2 (JNK2)-PHD1 mediated HIF-1α degradation [175]. Interestingly, expression of individual
PHD isoforms associates with good breast cancer patient outcome and PHD1 and PHD3 appear
to be important in breast cancer in a HIF independent manner [176]. PHD3 is expressed highly in
breast cancer patients with good prognosis and may be an important regulator of apoptosis in breast
cancer [176]. PHD studies in the lung cancer are even more limited. Some groups have looked at the
expression of PHD isoforms in lung cancer samples [177,178]. These studies show that PHDs are highly
expressed in lung cancer compared to normal tissues, and both collective and individual PHD isoform
expression are poor prognostic factors for NSCLC survival, independent of HIF levels [177,178]. As of
yet, no clear mechanistic links between PHDs and NF-κB activity, independent of HIF, have been made
in context of lung cancer and breast cancer.
7. Future Prospective in Cancer Therapeutics: Targeting HIF and the NF-κB Pathway
Due to the substantial contribution of HIF and NF-κB in carcinogenesis, over the years new
therapeutic strategies have been developed to specifically target these two pathways. Moreover,
considering their intimate crosstalk, it is possible that some of the therapeutics and modulators used
might exert their function on both transcription factors. So far, HIF signalling has been altered mainly
through PHD inhibitors, which have been beneficial in the treatment of several cancers, including those
characterised by prominent inflammation. PHD inhibition can stabilise HIF-α, but also activate other
pathways, such as NF-κB [72,91], promoting an inflammatory resolution. To date, five PHD inhibitors
(BAY-853934, JTZ-951, FG-4592, AKB-6548 and GSK1278863) have entered clinical trials. However,
some concerns about their side or off target effects exist, considering the different substrate specificity
and cellular expression of the three enzymatic isoforms identified so far [179]. An alternative approach
to target HIF stabilisation might be via the inhibition of the HIF-E3 ubiquitin ligase responsible for
HIF degradation. Given that neddylation has been shown to modulate HIF via Cullin-2, MLN-4924,
an adenosine monophosphate analog able to deneddylate cullin proteins, can act as a potent HIF
stabilizer in vitro and in vivo, being also a viable tool in the treatment of cancer cells [180,181].
Additionally, VHL inhibitors represent an attractive alternative to PHD inhibitors. Recently, our group
described VH298, a novel potent chemical probe blocking protein-protein interaction between VHL
and HIF-α, downstream of HIF-α hydroxylation. Importantly, this small molecule highly selectively
stabilises the hydroxylated form of HIF-1α and HIF-2α, in a concentration- and time-dependent
manner, in both cancerous and non-cancerous primary cells, inducing a HIF-dependent hypoxic
response [179]. On the other hand, several studies questioned the efficacy of a therapeutic activation of
HIF, since this signaling pathway is directly involved in tumor promotion, as previously mentioned.
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Therefore, several other compounds are currently in clinical trials as HIF-1α inhibitors, although, in
many cases, they were originally intended to target different pathways (i.e., PI3K/mTOR inhibitors,
microtubules targeting agents, cardiac glycosides, topoisomerase inhibitors, among others) [182].
HIF-1α and HIF-2α have often divergent roles in tumorigenesis, hence the necessity to selectively
target one or the other. AKB-4924 is a PHD inhibitor tested in inflammation models, showing a
relative selectivity for HIF-1α versus HIF-2α [183]. However, no HIF-1α specific inhibitors have been
discovered so far, although great efforts have been made to identify inhibitors exerting their function
by decreasing mRNA or protein level of HIF-1α, preventing its dimerization or DNA/co-activators
binding. For long time, HIF-2α has been considered undruggable, till the revolutionary discovery of
two small molecules, PT2399 and the closely related analogue PT2385. These compounds function as
potent HIF-2α antagonists, being able to bind to a large cavity located in the PAS-B domain of HIF-2α,
thus disrupting the hetero-dimerization between HIF-2α and HIF-1β [184,185]. These small molecules
have a promising clinical potential, considering that they reduced tumour growth and decreased
tumour vascular area in VHL−/− clear cell Renal Cell Carcinoma (ccRCC) patient derived xenographs,
showing even greater efficacy than conventional treatments (i.e., sunitinib) [184–186].
As previously explained, not only HIF, but also NF-κB is a key player in many aspects of
cancer development and progression. For this reason, the possibility to target directly NF-κB for
cancer therapy has been an important subject of research. On one side, due to the deep link
between inflammation and cancer, it would be ideal to prevent or treat tumour formation by
blocking inflammation [44]. On the other side, in the light of the multiple functions of NF-κB in
the innate and adaptive immune responses, the use of NF-κB inhibitors would not be recommended
to treat malignancies, especially in the tumour-eliminating phase, when immune cells specifically
target transformed cells. Nevertheless, using chemotherapeutics in combination with inhibitors of
NF-κB seems to be currently the preferred approach, in particular when tumours feature chronic
inflammation [5]. Many well-known NSAIDs, such as aspirin and ibuprofen, can be used to this
scope. In fact, at low doses, aspirin has been suggested to prevent some types of cancer, including
colorectal cancer [187], whereas at high doses, aspirin can inhibit the kinase activity of IKK or
interfere with the degradation of IκBα, blocking NF-κB activity. Alongside NSAIDs, anti-inflammatory
and anti-cancer activities have been recognised for a number of natural products, glucocorticoids,
immunosuppressants, or inhibitors of other pathways, directly affecting the NF-κB induction or
signalling cascade, the translocation of NF-κB to the nucleus, the DNA binding of the dimers or their
interactions with the transcriptional machinery [3].
The use of NF-κB inhibitors has been shown to be important also to enhance the activity of
immunotherapy. In a recent study, a combined use of IL-18 as immunotherapeutic agent alongside
a targeted inhibition of the NF-κB pathway emerged as potentially effective against pancreatic
cancer [188]. Recently, cancer immunotherapy effectiveness has been boosted by a better understanding
of immune checkpoints. Programmed Death 1 (PD1)/Programmed Death Ligand 1 (PD-L1) and
Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) are the most critical immune checkpoints.
Both of them are used by tumours to escape host immune surveillance, although they have distinct
expression and mechanisms of action in the regulation of T cell activity [189]. Given the importance
of the hypoxic tumour microenvironment for TAMs and tumour-infiltrating myeloid cells, it is not
surprising that PD-L1 was identified as a direct HIF-1α target gene in myeloid-derived suppressor cells
(MDSCs) [190]. Several reports correlated a high expression of PD-L1 to a poor prognosis in a number
of solid cancers. Thus, immune checkpoint blockade with monoclonal antibodies directed against
PD-1 and PD-L1 has proven to be powerful compared to conventional chemotherapies, activating an
anti-tumour immunity able to recognise specifically tumour derived antigens, even when they have
undergone mutations [189]. Several PD1 and PD-L1 antibodies are currently in clinical trials (reviewed
in [189]), representing surely the next generation of the immune modulators. However, whether HIF
and NF-κB crosstalk extends to immunosuppression has yet to be formally investigated and surely is
an area of extreme importance.
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NF-κB signalling is upregulated in cells having a compromised expression of the tumour
suppressor pVHL, such as ccRCC cells, where VHL is inactivated [191]. In this cellular context, Vascular
Cell Adhesion Molecule 1 (VCAM-1) expression was found to be regulated by the non-canonical
NF-κB pathway. Importantly, VCAM-1 decreased following VHL loss or after hypoxia exposure
and PHD inactivation [192]. Recently, the mechanisms by which pVHL might directly impact on
the NF-κB pathways have been proposed. Wang and colleagues demonstrated that pVHL mediates
the K63-ubiquitination of IKKβ. Surprisingly, this modification does not lead to degradation, but
prevents TAK1-IKKβ interaction, and consequent IKKβ phosphorylation and NF-κB activation [193].
Considering this novel function of pVHL regulating the NF-κB pathway, new therapeutic possibilities
might be speculated, especially to inhibit the aberrant activation of the NF-κB pathway in some
neoplastic contexts. Therefore, further studies are needed in this promising direction, as the main
challenge for researchers in this field is still to directly target NF-κB, as well as HIF, only in
transformed cells.
8. Conclusions
NF-κB and HIF crosstalk occurs at many levels, from shared activators to shared target genes.
However, context specificity exists and this is an important determinant in whether this crosstalk can
be used for future therapeutic intervention. Since, pharmacological interventions for both pathways are
available, future studies investigating the role of HIF modulators on the NF-κB pathway are underway
with the aim of broadening the use of these compounds in the clinic. Furthermore, the identification of
novel compounds targeting specific transcription factor dimers such as HIF-2α-HIF-1β also opens the
possibility of specifically targeting NF-κB dimers in the future.
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